Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 OTO-104 in unilateral Meniere's disease
2015-004496-71Phase 3Terminated
- Sponsor
- Otonomy, Inc.
- Start
- Dec 2015
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Meniere Disease comparing OTO-104 intratympanic injection with Placebo intratympanic injection (2 arms). Primary endpoint: Definitive vertigo days at Week 12. Started Dec 2015; status: terminated.
02
Drugs
Otividex
03
Conditions
Meniere Disease
Beyond the preview
Go deeper on 2015-004496-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004496-71.